Patents by Inventor Michael Schmitt

Michael Schmitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12258629
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 25, 2025
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 12241123
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: March 4, 2025
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20250019761
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: April 26, 2024
    Publication date: January 16, 2025
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20250009877
    Abstract: This disclosure relates to methods of treating cancer using a combination of an anti-CD40 antibody such as SEA-CD40, and an anti-PD-1 antibody such as pembrolizumab. The treatment can further include a chemotherapy.
    Type: Application
    Filed: July 28, 2022
    Publication date: January 9, 2025
    Inventors: Michael Schmitt, Shyra J. Gardai
  • Publication number: 20250011866
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: April 4, 2024
    Publication date: January 9, 2025
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240417793
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: April 29, 2024
    Publication date: December 19, 2024
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240368692
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: May 13, 2024
    Publication date: November 7, 2024
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240368691
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: April 30, 2024
    Publication date: November 7, 2024
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240368689
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: April 29, 2024
    Publication date: November 7, 2024
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240368690
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Application
    Filed: April 30, 2024
    Publication date: November 7, 2024
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240299741
    Abstract: Electrical stimulation systems and methods for preventing and treating pressure ulcers is provided. The system includes a washable sheet with one or more conductive signal pathways and integral or removable electrodes and a connectable controller that cooperates with the sheet and electrodes to provide periodic electrical stimulation to a patient's skin. Various sensors may provide feedback and optional closed-loop control. The electrical stimulation patterns may help maintain tissue health, prevent development or worsening of pressure ulcers, or manage pain.
    Type: Application
    Filed: May 15, 2024
    Publication date: September 12, 2024
    Inventors: Michael Howard Finkelstein, Dennis Michael Schmitt
  • Publication number: 20240293666
    Abstract: An electrical stimulation training and neuromuscular rehabilitation system including a machine-washable stimulation suit with multiple electrodes to provide controlled stimulation of various muscle groups is provided. The stimulation suit may also include one or more integrated biosensors to provide diagnostic capability in addition to stimulation. The system may also include a software platform executable on a user computing device (such as a tablet) that may facilitate control of the stimulation programs (e.g., intensity level, duration, isolation of individual muscle groups vs. full body stimulation) of one or more stimulation suits by the wearer or a fitness practitioner or trainer and/or that may facilitate intervention by a medical provider through a remote telemedicine platform.
    Type: Application
    Filed: October 6, 2023
    Publication date: September 5, 2024
    Inventors: Michael Howard Finkelstein, Dennis Michael Schmitt, Jana Schmitt
  • Publication number: 20240226398
    Abstract: A mobile interface cart including a storage tank for receiving effluent from a dialysis (e.g., hemodialysis) procedure and a pump for pumping the effluent from the storage tank to an external waste drain located in the treatment center. In use, the pump enables the effluent to be moved over greater distances and/or around obstacles thereby eliminating, or at least minimizing, the need to construct expensive and time-consuming waste drains in the treatment center.
    Type: Application
    Filed: October 25, 2022
    Publication date: July 11, 2024
    Inventors: Kenneth Nelson, Juliet Hildreth, Steven Michael Schmitt
  • Patent number: 12024747
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 2, 2024
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Patent number: 12006545
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: June 11, 2024
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240182417
    Abstract: The present invention relates to a process for preparing N,N?-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine. The present invention further relates to the use of N,N?-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine to prepare poly[[6-[(1,1,3,3-tetramethylbutyl)amino]-s-triazine-2,4-diyl]-[(2,2,6,6-tetramethyl-4-piperidyl)imino]-hexamethylene-[(2,2,6,6-tetramethyl-4-piperidyl)imino], reaction material of 1,6-hexanediamine, N,N?-bis (2,2,6,6-tetramethyl-4-piperidine-yl),2,4,6-trichloro-1, 3,5-triazine,N-butyl-1-butylamine, and N-butyl-2,2,6,6-tetramethyl-4-piperidineamine, N,N?-bis(2,2,6,6-tetramethyl-4-piperidyl)-N,N?-diformylhexamethylenediamine, and 1,6-Hexanediamine, N,N?-bis(2,2,6,6-tetramethyl-4-piperidinyl)-, polymer with 2,4-dichloro-6-(4-morpholinyl)-1,3,5-triazine.
    Type: Application
    Filed: February 10, 2022
    Publication date: June 6, 2024
    Inventors: Alexander Michael HAYDL, Michael SCHMITT, Elena CAPITO'
  • Patent number: 11999939
    Abstract: A predictive model is described that can predict parameter concentrations in the future based on initial, measured concentrations and historical data. A plurality of multivariate techniques can be used to construct the predictive model capable of forecasting concentrations over multiple and diverse cell lines. The predictive model is also scalable. In one embodiment, a future lactate concentration trajectory is determined and at least one condition within a bioreactor is changed or modified to maintain lactate concentration within desired ranges.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: June 4, 2024
    Assignee: LONZA LTD
    Inventors: Brandon John Downey, John Michael Schmitt, Jeffrey Francis Breit
  • Patent number: 11993815
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: May 28, 2024
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt
  • Publication number: 20240153069
    Abstract: The invention relates to a method for testing quality of an object in a real environment using a camera, an optical display device, and a processing apparatus, the method including the following steps: defining a test geometry and a reference geometry in a computer-assisted data mode; defining a test pose, in which the camera should be placed by the user as target positioning for a quality test to be carried out of the object to be tested; and visualizing the test pose on the optical display device. In a second phase, at least one image of the real environment is captured by the camera, the pose of which camera is in a range that includes the test pose, and the test geometry and the reference geometry in the image are tracked. Furthermore, a pose of the tracked test geometry in relation to the reference geometry and at least one parameter are determined on the basis of how the pose of the tracked test geometry is in relation to a target pose of the test geometry defined within the data model.
    Type: Application
    Filed: December 14, 2021
    Publication date: May 9, 2024
    Inventors: Florian Schmitt, Michael Schmitt, Sarah Grohmann, Benjamin Audenrith, Lukas Giesler
  • Patent number: 11970740
    Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: April 30, 2024
    Assignee: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventors: Jesse Salk, Lawrence A. Loeb, Michael Schmitt